Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,827 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 29.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 16,978 shares of the biopharmaceutical company’s stock after acquiring an additional 3,827 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Theravance Biopharma were worth $137,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in Theravance Biopharma in the third quarter worth about $60,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Theravance Biopharma in the 2nd quarter worth approximately $108,000. Ballentine Partners LLC bought a new position in Theravance Biopharma during the 3rd quarter valued at approximately $104,000. Finally, XTX Topco Ltd purchased a new position in Theravance Biopharma during the second quarter valued at $129,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Up 1.1 %

Shares of NASDAQ TBPH opened at $9.99 on Tuesday. The firm has a market cap of $491.21 million, a P/E ratio of -9.89 and a beta of 0.23. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $11.71. The company has a 50 day moving average of $8.90 and a 200 day moving average of $8.73.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same period in the previous year, the company earned ($0.17) earnings per share. As a group, equities analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.